UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
April 27, 2026
________________
NOVO NORDISK A/S
(Exact name
of Registrant as specified in its charter)
Novo Allé 1
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F
Form 20-F ☒
Form 40-F ☐
Novo Nordisk A/S – Share repurchase programme
Bagsværd, Denmark, 27 April 2026
– On 4 February 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014
of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the
“Safe Harbour Rules”). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed
during a 12-month period beginning 4 February 2026.
Under the programme initiated 4 February 2026, Novo Nordisk will repurchase
B shares for an amount up to DKK 3.8 billion in the period from 4 February 2026 to 4 May 2026.
Since the announcement 20 April 2026, the following transactions have been made:
Number
of
B shares
Average
purchase
price
Transaction
value, DKK
Accumulated,
last announcement
12,257,992
3,148,710,807
20
April 2026
230,000
255.92
58,861,892
21
April 2026
230,000
255.95
58,868,391
22
April 2026
230,000
249.65
57,420,415
23
April 2026
230,000
249.19
57,313,744
24
April 2026
230,000
251.11
57,755,946
Accumulated
under the programme
13,407,992
3,438,931,195
The details for each transaction made under
the share repurchase programme are published on novonordisk.com.
With the transactions stated above, Novo Nordisk owns a total of 30,797,791 B shares
of DKK 0.10 as treasury shares, corresponding to 0.7% of the share capital. The total amount
of A and B shares in the company is 4,465,000,000 including treasury shares.
Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion
during a 12-month period beginning 4 February 2026. As of 24 April 2026, Novo Nordisk has since 4 February 2026 repurchased a total 13,407,992
B shares at an average share price of DKK 256.48 per B share equal to a transaction value of DKK 3,438,931,195.
Novo Nordisk is a leading global healthcare company founded
in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes.
We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease.
Novo Nordisk employs about 68,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk’s B shares
are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X,
LinkedIn and YouTube.
Contacts
for further information
Media:
Liz
Skrbkova (US)
Ambre James-Brown
+1 609 917
0632
+45 3079 9289
lzsk@novonordisk.com
globalmedia@novonordisk.com
Investors:
Michael Novod
Jacob Martin
Wiborg Rode
+45 3075 6050
+45 3075 5956
nvno@novonordisk.com
jrde@novonordisk.com
Max Ung
Sina Meyer
+45 3077 6414
+45 3079 6656
mxun@novonordisk.com
azey@novonordisk.com
Alex Bruce
Christoffer
Sho Togo Tullin
+45 34 44 26 13
+45 3079 1471
axeu@novonordisk.com
cftu@novonordisk.com
Frederik Taylor Pitter
Mads Berner
Bruun
+1 609 613 0568
+45 3075 2936
fptr@novonordisk.com
mbbz@novonordisk.com
Company announcement No 28
Page 2 of 2
Novo Nordisk A/S
Investor Relations
Novo Allé 1
2880 Bagsværd
Denmark
Telephone:
+45 4444 8888
www.novonordisk.com
CVR no: 24 25 67 90
Company
announcement No 28 / 2026
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
Date: April 27, 2026
NOVO NORDISK A/S
Maziar Mike Doustdar
Chief Executive Officer